Company profile for Coya Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patie...
The company’s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5850 San Felipe St, Suite 500, Houston, Texas 77057
Telephone
Telephone
1 (800) 587-8170
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

ASPEN

ASPEN

Not Confirmed

envelop Contact Supplier

ASPEN

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260130653717/en/Coya-Therapeutics-Announces-%2411.1-Million-Private-Placement

BUSINESSWIRE
30 Jan 2026

https://www.businesswire.com/news/home/20260120977124/en/Coya-Therapeutics-CEO-Dr.-Arun-Swaminathan-Issues-Letter-to-Stockholders

BUSINESSWIRE
20 Jan 2026

https://www.pharmiweb.com/press-release/2026-01-08/coya-therapeutics-announces-results-of-investigator-initiated-study-of-ld-il-2-and-ctla4-ig-demonstr

PHARMIWEB
08 Jan 2026

https://www.businesswire.com/news/home/20260105080790/en/Coya-Therapeutics-Announces-U.S.-FDA-Acceptance-of-Investigational-New-Drug-IND-Application-for-COYA-302-for-the-Treatment-of-Frontotemporal-Dementia-FTD

BUSINESSWIRE
05 Jan 2026

https://www.businesswire.com/news/home/20251223853357/en/Coya-Therapeutics-Receives-Clinical-Trial-Application-CTA-Acceptance-from-Health-Canada-to-Proceed-with-the-COYA-302-ALSTARS-Trial-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS

BUSINESSWIRE
23 Dec 2025

https://ir.coyatherapeutics.com/news/news-details/2025/Coya-Therapeutics-Announces-Patients-Have-Been-Dosed-in-the-ALSTARS-Trial-of-COYA-302-for-the-Treatment-of-ALS/default.aspx

PRESS RELEASE
09 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty